We need better tools for assessing new medicines – and to develop them, we must work together.

In the pharma industry of the future, only the strongest companies will survive – and that means those with the most successful collaborations.

Autocrine-based screening has identified a more selective anti-diabetic drug candidate

CRISPR has brought gene editing into the mainstream – but where should we draw the line?

Data from a large-scale trial suggest that screening cuts ovarian cancer mortality rates by 25 percent – but some remain skeptical

Could cell-based synthetic circuits make pills and ointments a thing of the past for chronic disease?

Michela Gallagher was studying aging in lab rats when an unusual finding launched her on a translational journey that now sees her poised to initiate a Phase III trial of a drug to delay the onset of Alzheimer’s dementia.

As a neurologist, Bradley Hyman has seen first-hand the impact of Alzheimer’s disease on patients and their families.

Our understanding of the mechanisms that trigger Alzheimer’s disease is growing fast, but many secrets still lurk in the shadowy recesses of the brain.

Better understanding of human biology presents us with an opportunity to combat disease on two fronts – targeting individual variation on one hand and universal mechanisms on the other.